ANPCY News and Press, Angle Plc Surrey ADR

GUILDFORD, SURREY / ACCESSWIRE / July 11, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that at the Annual General Meeting of the Company held earlier today, all resolutions were duly passed. For further information: Notes for editors About ANG...

GUILDFORD, SURREY / ACCESSWIRE / June 18, 2024 / ANGLE plc ("the Company") (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces that the audited Annual Report a...

PARSORTIX SYSTEM AND ASSAYS BEING SHOWCASED AT THE 2024 ANNUAL CONGRESS OF THE EUROPEAN ASSOCIATION FOR CANCER RESEARCH ANGLE presenting two posters highlighting the utility of CTC & ctDNA dual analysis and ANGLE's DNA Damage Response assay GUILDFORD, SURREY / ACCESSWIRE / June 11, ...

INDEPENDENT STUDY OF OVARIAN CANCER CTCS HARVESTED BY THE PARSORTIX SYSTEM HIGHLIGHTS POTENTIAL TO PREDICT PROGRESSION FREE SURVIVAL FOR DRUG TRIALS The study investigated 123 metastatic ovarian cancer patients over two and a half years using the Parsortix system to assess 474 longitudinal p...

ANGLE commissioned to develop a Parsortix-based Androgen Receptor detection assay for use in prostate cancer studies GUILDFORD, SURREY / ACCESSWIRE / May 3, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions...

2024-04-24 03:16:41 ET More on Angle Plc, AstraZeneca, etc. What AstraZeneca Is Getting Through The Acquisition Of Fusion Pharmaceuticals 5 Reasons AstraZeneca Stock Can Rise In 2024 AstraZeneca PLC (AZN) Q4 2023 Earnings Call Transcript AstraZeneca Imfinzi l...

ANGLE signs agreement to tailor existing Parsortix-based DNA damage response assay for use in pharmaceutical R&D GUILDFORD, SURREY / ACCESSWIRE / April 24, 2024 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutio...

Proprietary cell recovery device and method eliminates over 70% of CTC cell loss from standard microscopy techniques increasing assay sensitivity GUILDFORD, SURREY / ACCESSWIRE / April 22, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circula...

PARSORTIX HER2 ASSAY SHOWCASED AT PRESTIGIOUS INTERNATIONAL CANCER CONFERENCE CTC HER2 assay being developed for HER2 targeted drugs and antibody drug conjugates presented at internationally renowned AACR Annual Meeting 2024 GUILDFORD, SURREY / ACCESSWIRE / April 8, 2024 / ANG...

PARSORTIX SYSTEM AND ASSAYS BEING SHOWCASED AT A LEADING EUROPEAN BREAST CANCER CONFERENCE ANGLE presenting two posters highlighting the utility of the Company's new Portrait+ CTC Staining Kit and Portrait HER2 assay GUILDFORD, SURREY / ACCESSWIRE / March 22, 2024 / ANGLE plc (AIM:AG)(O...